GMAB:NSD-Genmab A/S (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 38.74

Change

+1.82 (+4.93)%

Market Cap

USD 24.43B

Volume

0.52M

Avg Analyst Target

USD 46.00 (+18.74%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

Genmab A/S (GMAB) Stock Analysis:
Based on the Genmab A/S stock forecasts from 10 analysts, the average analyst target price for Genmab A/S is USD 46.00 over the next 12 months. Genmab A/S’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Genmab A/S is Bullish , which is based on 10 positive signals and 3 negative signals. At the last closing, Genmab A/S’s stock price was USD 38.74. Genmab A/S’s stock price has changed by +0.22 % over the past week, -7.72 % over the past month and +0.23 % over the last year.

About

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease ...Read More

Company Website : https://www.genmab.com

Address : Kalvebod Brygge 43, Copenhagen, Denmark, 1560

Employees : 1,136

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 0.69

52 Week High : 49.07

Short Ratio : 4.19

52 Week Low : 30.10

Shorted Shares : 1,430,950

200 Day Moving Average : 40.83

Shorted Shares Previous Month : 1,265,097

50 Day Moving Average : 42.96

Shares Held by Institutions : 7.18%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-12-07 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

+17.02 (+6.41%)

 USD122.24B 18.38 14.64
BNTX BioNTech SE

+22.86 (+8.17%)

 USD83.44B 8.87 7.65
REGN Regeneron Pharmaceuticals Inc

+10.09 (+1.61%)

 USD68.31B 10.00 7.78
VRTX Vertex Pharmaceuticals Incorpo..

+0.16 (+0.08%)

 USD51.82B 24.59 15.60
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
BGNE BeiGene Ltd

+18.04 (+6.03%)

 USD33.26B N/A N/A
SGEN Seagen Inc

+0.43 (+0.29%)

 USD27.56B 55.02 44.86
ALNY Alnylam Pharmaceuticals Inc

+3.28 (+1.85%)

 USD20.49B N/A N/A
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A
TECH Bio-Techne Corporation

+4.72 (+1.01%)

 USD17.92B 107.96 64.40

ETFs Containing GMAB

Symbol Name Weight Mer Price(Change) Market Cap

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.72% 72% C- 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.72% 72% C- 37% F
Trailing 12 Months  
Capital Gain 0.23% 72% C- 42% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.23% 72% C- 40% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 30.68% 65% D 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.68% 64% D 75% C
Risk Return Profile  
Volatility (Standard Deviation) 33.15% 80% B- 54% F
Risk Adjusted Return 92.56% 98% A+ 91% A-
Market Capitalization 24.43B 99% A+ 96% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 55.83 17% F 18% F
Price/Book Ratio 7.50 16% F 16% F
Price / Cash Flow Ratio 3.80 8% F 48% F
EV/EBITDA 6.05 36% F 75% C
Management Effectiveness  
Return on Equity 14.45% 96% A 79% C+
Return on Invested Capital 31.16% 92% A- 93% A
Return on Assets 8.57% 96% A 90% A-
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 4.19 51% F 34% F
Short Percent 0.17% 97% A+ 91% A-
Beta 0.69 77% C+ 76% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.